Effects of low-dose Aspirin in bipolar disorder – a randomized controlled trial
BD is increasingly conceived as a multisystem disorder with inflammation confirmed to be involved in the pathogenesis. Emerging yet compelling data converge to suggest that low-dose Aspirin may protect against its onset and deterioration. The present study is the first double-blinded randomized placebo-controlled trial investigating whether low-dose Aspirin versus placebo as add-on to standard treatment improves mood stabilization and other critical patient outcomes in 250 subjects with BD, and whether its principal effects are antimanic, antidepressant or prophylactic against relapse.
For further information, please contact: Caroline Fussing